Govind Pandey
Ex-Professor/Principal Scientist & Head of Pharmacology (Pharmacy),
presently Officer-In-Charge of Rinder Pest (Veterinary/Animal Husbandry
Department, Govt. of MP), Jabalpur Division, Jabalpur, M.P., India
Email: drgovindpandey@rediffmail.com
Abstract: The present study was taken to evaluate the hepatogenic effect of OptiLiv (a polyherbal formulation) on estrogen induced liver damage in female albino rat. The rats of groups 2 and 3 were administered with ethinyl oestradiol (EO, a semi-synthetic estrogen) @ 500 μg/kg body weight, orally, weekly for 8 weeks. The rats of group 1 were given saline to serve as normal. From the 9th week, the rats of group 3 were administered with OptiLiv @ 100 mg/kg, orally, daily for 3 weeks; while the rats of group 2 were kept without treatment of OptiLiv for 3 weeks after EO administration. The rats were sacrificed after the experimental periods, and the histopathological study of livers was performed. On the 12th week, the hepatic tissues of group 2 revealed congestion, cellular swelling and focal areas of hydropic changes (vacuolization). The blood vessels, including central veins were also congested. At places, the sinusoids were dilated. Hepatocytes showed nuclear granularity of cytoplasm, indicating the degenerative changes in between the hepatic lobules. However, the hepatic tissues of group 3 showed very mild changes, and regeneration and normalization of many hepatocytes were observed. The results suggest that estrogen (EO) caused the liver damage, which was subsided and repaired to a great extent by OptiLiv.
Keywords: Ethinyl oestradiol (EO, estrogen), Liver damage, OptiLiv, Hepatogenic effect, Female Rat.
REFERENCES
Biswas, N.R.;Vardhani,A.;Mongre, P.K.; Biswas, A.; Pandey, R.M. and Mathur, A.K. (1999). Double blind randomized clinical trial of a herbal formulation “OptiLiv” in acute viral hepatitis. JK-Practitioner, 6: 54-57.
Chopra,R.N.,Nayar, S.L. and Chopra,I.C.‑(2002). Glossary of Indian Medicinal Plants. CSIR, New Delhi, India.
CSIR (1986). The Useful Plants of India. New Delhi, India.
Culling, C.F.A. (1963). Hand Book of Histological Techniques, 2nd edn. Butterworth & Co. Ltd., London. pp. 25-172.
Gupta, V.K. and Sharma, S.K. (2006). Plants as natural antioxidants. Nat. Prod. Rad., 5(4): 326-334.
Hertz, R. (1976). The estrogen-cancer hypothesis. Cancer, 38(1): 534-540.
Kathiresan, K.; Boopathy, N.S. and Kavitha, S. (2006). Coastal vegetation-An underexplored source of anticancer drugs. Nat. Prod. Rad., 5(2): 115-119.
Kumar, Vikas; Das, S.N. and Agrawala, S.K. (2002). Neutralising effect of OptiLiv and EuMilon glucose intolerance in ethyl alcohol administered rats. Phytomedica, 3: 91-94.
Loose, D.S. and Stancel, G.M. (2006). Estrogens and progestins. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th edn. (Brunton, L.L., ed.). McGraw-Hill Co., New York. pp. 1541-1571.
Madhuri, S. (2008). Studies on oestrogen induced uterine and ovarian carcinogenesis and effect of ProImmu in rats. PhD thesis, RDVV, Jabalpur, MP.
Madhuri S. and Pandey, Govind (2010). Effect of ProImmu, a herbal drug on estrogen caused uterine and ovarian cytotoxicity. biomed, 5(1): 57-62.
Mathur, A.K.; Chatterjee, S.; Agrawala, S.K. and Jain, A.K. (1996). Safety and tolerability of OptiLiv, a polyherbal formulation in healthy human volunteers. Indian J. Indg. Med., 18: 179-182.
Pandey, Govind and Madhuri, S. (2008). Median lethal dose, acute and chronic toxicities of ethinyl oestradiol estrogen. Natl. J. Life Sci., 5(2): 291-294.
Pandey, Govind and Madhuri, S. (2007). Efficacy of OptiLiv, a herbal formulation against oestrogen induced liver damage in female rats. Int. J. Green Pharm., 1(3-4): 39-41.
Pandey, Govind P. (1990). Hepatogenic effect of some indigenous drugs on experimental liver damage. PhD thesis, JNKVV, Jabalpur, MP.
Sharma, R.K.; Trivedi, P.; Sharma, Varsha and Garg, U.K. (2005). Histopathological evaluation of certain hepatoprotective herbal and non-herbal formulations in rats. Indian Vet. J., 82(12): 1267-1269.Singh, V.K. (2000). Efficacy of a herbal formulation ‘OptiLiv’ against hepatotoxicity of anti-tuberculosis drugs: Double blind study. JK-Practitioner,7(4): 289-292.